Introduction to CABP7, A Potential Drug Target (G164633)

Target Name: CABP7

NCBI ID: G164633

CABP7

Introduction to CABP7, A Potential Drug Target

CABP7, also known as Calcium Binding Protein 7, is a protein that has gained significant attention as both a drug target and a potential biomarker in various pathological conditions. This article aims to discuss the importance of CABP7, its role in disease progression, and its potential applications in drug discovery and diagnostics.

The role of CABP7 in disease progression

CABP7 is a calcium binding protein that is predominantly expressed in the central nervous system, specifically in the brain. It belongs to the calmodulin-like protein family, which plays a crucial role in calcium signaling and intracellular calcium homeostasis. The dysregulation of calcium signaling pathways has been implicated in numerous diseases, including neurodegenerative disorders, psychiatric conditions, and cancer.

Studies have demonstrated that CABP7 interacts with voltage-gated calcium channels (VGCCs), facilitating calcium influx into cells. This interaction is crucial for the proper functioning of VGCCs, as it modulates their calcium-dependent activation and inactivation processes. Disruptions in this interaction can lead to aberrant calcium signaling, which has been linked to various disease states.

The potential of CABP7 as a drug target

Due to its involvement in calcium signaling and its specific expression in the brain, CABP7 has emerged as a promising drug target for several neurological disorders. For example, it has been shown that dysregulated calcium signaling contributes to the pathogenesis of neurodegenerative diseases such as Alzheimer's and Parkinson's. Targeting CABP7 and its interaction with VGCCs could potentially restore normal calcium dynamics and alleviate disease symptoms.

Several studies have focused on developing small molecules that can selectively bind to CABP7 and modulate its interaction with VGCCs. These molecules aim to enhance or inhibit the calcium influx through VGCCs, depending on the specific disease context. By fine-tuning calcium signaling, it is hoped that CABP7-targeted therapies can provide effective treatment options for neurological disorders.

Additionally, CABP7 has been implicated in psychiatric conditions such as schizophrenia and bipolar disorder. Altered calcium signaling has been observed in the brains of individuals with these disorders, and dysregulated CABP7-VGCC interactions have been proposed as contributing factors. Therefore, targeting CABP7 could potentially normalize calcium signaling in psychiatric patients, offering new therapeutic avenues.

CABP7 as a potential biomarker

In addition to its potential as a drug target, CABP7 holds promise as a biomarker for disease diagnosis and prognosis. Biomarkers are measurable molecules or characteristics that indicate the presence or progression of a disease. By identifying and quantifying biomarkers, healthcare professionals can enhance disease detection, monitor treatment response, and predict patient outcomes.

Research has shown altered levels of CABP7 in the brains and cerebrospinal fluid of individuals with neurodegenerative diseases. In Alzheimer's disease, for example, reduced CABP7 expression has been associated with disease severity and cognitive decline. Similarly, increased CABP7 expression has been detected in certain brain regions of Parkinson's disease patients.

Furthermore, studies have explored the use of CABP7 as a biomarker in psychiatric disorders. In schizophrenia, for instance, higher CABP7 levels have been found in the cerebrospinal fluid of affected individuals, suggesting its potential as a diagnostic tool. However, further research is needed to establish standard measurement techniques and determine the optimal cutoff values to maximize the clinical utility of CABP7 as a biomarker.

Conclusion

CABP7 is a protein that plays a critical role in calcium signaling, making it an attractive target for drug discovery in neurological disorders. Modulating its interaction with VGCCs could restore aberrant calcium dynamics and offer new treatment options. Moreover, CABP7 shows promise as a biomarker for disease diagnosis and prognosis. By further exploring the potential of CABP7 in both drug development and diagnostics, researchers can contribute to the advancement of precision medicine in various pathological conditions.

Protein Name: Calcium Binding Protein 7

Functions: Negatively regulates Golgi-to-plasma membrane trafficking by interacting with PI4KB and inhibiting its activity

The "CABP7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CABP7 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets